Mesoblast

MESO · ASX

$12.28−$0.27 (−2.15%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $12.55

MESO analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $25.07 (+104.2% upside)

Low: $19.45
Now: $12.28
High: $31.78

Upgrades and downgrades

The latest rating actions, newest first

MESO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Aug 27, 2026	Maintains	Overweight	$35.00 → $39.00	39%
Jefferies	Nov 25, 2025	Upgrade	Hold → Buy	—	67%

The case for and against

Updated Feb 16, 2025

Bull case

Mesoblast Ltd has demonstrated significant growth potential, with projected revenues from Ryoncil expected to increase from $24 million in 2025 to $368 million by 2032. The company’s enhanced enterprise value is now estimated at $3.16 billion, reflecting a substantial increase from previous valuations, driven by the potential of its therapies and international partnerships. Additionally, the promising clinical outcomes of Ryoncil, showing improved survival rates compared to available therapies, and the increase in valuation for multiple product candidates further support a positive outlook for the company's financial performance.

Bear case

Mesoblast Ltd faces significant challenges that contribute to a negative outlook for its stock. The company's reliance on JCR for TEMCELL sales may result in lower-than-expected royalty revenues, compounded by clinical trial risks that could negatively impact product approval timelines and success rates. Additionally, the potential inadequacies in safety and efficacy profiles, as highlighted by recent adverse event data and regulatory hurdles, further diminish confidence in the company’s ability to achieve its commercialization goals.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.